Healthcare Success

  The Non Invasive Prenatal Testing Market report incorporates in-depth study on major statistical analysis on influencing growth factors, business development plans, and on-going trend analysis. It focuses on key market dynamics that contains key drivers, restraints, opportunities and trends with regional segmentation and SWOT analysis. Non Invasive Prenatal Testing market research report provides qualitative and quantitative insights into sales value and volume, company profiles, competitors, and industry size (mainly covers product type, application and geography) and share estimations. It also gives comprehensive analysis on competitive landscape analysis (mainly company profiles, business demand, and new investment feasibilities), with revenue generations, CAGR status and potential growth factors. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690 Non Invasive Prenatal Testing (NIPT) Market is estimated to reach USD 7.3 billion by 2...

  The global non-invasive prenatal testing market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market. The non-invasive prenatal testing market is highly consolidated in nature with several big and emerging players. Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK) are some of the key players in the market. These players have adopted various growth strat...